title: Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
abstract: OBJECTIVE
  The purpose of the present study was to explore variation and prognostic significance of serum plasminogen activator inhibitor-1 (PAI-1) before the first cycle of chemotherapy and after the sixth cycle of chemotherapy in epithelial ovarian cancer (EOC) patients who had undergone cytoreductive surgery.
  
  
  METHODS
  We retrospectively evaluated the serum PAI-1 level of EOC patients and healthy controls and investigated the correlation between both serum PAI-1 levels of EOC patients we detected and clinicopathological characteristics. Survival rates were analyzed by using the Kaplan-Meier technique and Cox regression model.
  
  
  RESULTS
  Serum PAI-1 levels of EOC patients before the first cycle of chemotherapy and after the sixth cycle of chemotherapy were significantly higher than those of healthy controls (both P < 0.05). The results of Kaplan-Meier analysis indicated that both serum PAI-1 levels of EOC patients were associated with progression-free survival and overall survival. Multivariate Cox regression analysis revealed the PAI-1 level before the first cycle of chemotherapy was an independent prognostic marker of progression-free survival (28.4 vs 49.6 months; P = 0.013) and overall survival (41.8 vs 53.8 months; P = 0.043).
  
  
  CONCLUSIONS
  Both serum PAI-1 levels of EOC patients we detected were associated with International Federation of Gynecology and Obstetrics stage, residual tumor size and lymph node metastasis. The serum PAI-1 level before the first cycle of chemotherapy is an independent predictor for EOC patients.
authors.affiliation: Tongji Hospital, Tongji University, Shanghai, China.
authors.forename: Shutong
authors.initials: S
authors.lastname: Chen
authors.forename: Haifeng
authors.initials: H
authors.lastname: Tai
authors.forename: Xiaowen
authors.initials: X
authors.lastname: Tong
authors.forename: Jianjun
authors.initials: J
authors.lastname: Wang
authors.forename: Fang
authors.initials: F
authors.lastname: Yang
authors.forename: Yang
authors.initials: Y
authors.lastname: Yang
authors.forename: Ouyang
authors.initials: O
authors.lastname: Yiqin
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D016190:Carboplatin / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D017024:Chemotherapy, Adjuvant; D002681:China / Q000453:epidemiology; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures; D005260:Female; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D016190:Carboplatin; D017239:Paclitaxel
keywords: chemotherapy; epithelial ovarian cancer; plasminogen activator inhibitor 1; prognosis